BRPI0905645B8 - vacina de dna contra o vírus da febre amarela - Google Patents

vacina de dna contra o vírus da febre amarela

Info

Publication number
BRPI0905645B8
BRPI0905645B8 BRPI0905645A BRPI0905645A BRPI0905645B8 BR PI0905645 B8 BRPI0905645 B8 BR PI0905645B8 BR PI0905645 A BRPI0905645 A BR PI0905645A BR PI0905645 A BRPI0905645 A BR PI0905645A BR PI0905645 B8 BRPI0905645 B8 BR PI0905645B8
Authority
BR
Brazil
Prior art keywords
yfe
yellow fever
construct
against yellow
fever virus
Prior art date
Application number
BRPI0905645A
Other languages
English (en)
Inventor
Torres De Azevedo Marques Ernesto
Dhalia Rafael
Maciel Filho Romulo
Original Assignee
Fundacao Oswaldo Cruz
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to BRPI0905645A priority Critical patent/BRPI0905645B8/pt
Application filed by Fundacao Oswaldo Cruz filed Critical Fundacao Oswaldo Cruz
Priority to US13/504,464 priority patent/US9393296B2/en
Priority to EP10825869.0A priority patent/EP2495325B1/en
Priority to PCT/BR2010/000352 priority patent/WO2011050431A2/pt
Priority to AU2010312258A priority patent/AU2010312258B2/en
Priority to ES10825869.0T priority patent/ES2605654T3/es
Priority to CA2778893A priority patent/CA2778893C/en
Publication of BRPI0905645A2 publication Critical patent/BRPI0905645A2/pt
Priority to CL2012001093A priority patent/CL2012001093A1/es
Priority to PE2012000573A priority patent/PE20130341A1/es
Priority to ZA2012/03862A priority patent/ZA201203862B/en
Priority to ECSP12011928 priority patent/ECSP12011928A/es
Priority to US15/204,077 priority patent/US10124052B2/en
Priority to US16/146,369 priority patent/US10888612B2/en
Publication of BRPI0905645B1 publication Critical patent/BRPI0905645B1/pt
Publication of BRPI0905645B8 publication Critical patent/BRPI0905645B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24171—Demonstrated in vivo effect
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

vacina de dna contra o vírus da febre amarela. a presente invenção se refere a vacinas de dna codificando seqüências virais específicas. as vacinas de dna contra a febre amarela, desenvolvidas de acordo com a invenção, são baseadas na seqüência que codifica a proteína do envelope de vfa (p/yfe) . além da construção selvagem p/yfe, a seqüência e foi ainda fusionada à seqüência que codifica a proteína de associação à membrana lisossomal humana (h-lamp), gerando a construção (pl/yfe) . os resultados da invenção são considerados bastante promissores uma vez que as duas construções são capazes de induzir resposta de célula t contra os mesmos epítopos induzidos pela vacina 17dd, e a construção pl/yfe foi ainda capaz de induzir anticorpos neutralizantes numa concentração considerada satisfatória. o vetor pl/yfe foi ainda inoculado em camundongos, para posterior desafio intracerebral com vfa. surpreendentemente, 100% dos camundongos imunizados com pl/yfe sobreviveram ao desafio.
BRPI0905645A 2009-10-27 2009-10-27 vacina de dna contra o vírus da febre amarela BRPI0905645B8 (pt)

Priority Applications (13)

Application Number Priority Date Filing Date Title
BRPI0905645A BRPI0905645B8 (pt) 2009-10-27 2009-10-27 vacina de dna contra o vírus da febre amarela
US13/504,464 US9393296B2 (en) 2009-10-27 2010-10-26 DNA vaccine against virus of yellow fever
EP10825869.0A EP2495325B1 (en) 2009-10-27 2010-10-26 Dna vaccine against virus of yellow fever
PCT/BR2010/000352 WO2011050431A2 (pt) 2009-10-27 2010-10-26 Vacina de dna contra o vírus da febre amarela
AU2010312258A AU2010312258B2 (en) 2009-10-27 2010-10-26 DNA vaccine against virus of yellow fever
ES10825869.0T ES2605654T3 (es) 2009-10-27 2010-10-26 Vacuna de ADN contra el virus de la fiebre amarilla
CA2778893A CA2778893C (en) 2009-10-27 2010-10-26 Dna vaccine against the yellow fever virus
CL2012001093A CL2012001093A1 (es) 2009-10-27 2012-04-26 Vacuna de adn basada en la region que codifica la envoltura del virus de la fiebre amarilla fusionada a lamp; y antigeno de vacuna.
PE2012000573A PE20130341A1 (es) 2009-10-27 2012-05-08 Vacuna de adn contra el virus de la fiebre amarilla
ZA2012/03862A ZA201203862B (en) 2009-10-27 2012-05-25 Dna vaccine against virus of yellow fever
ECSP12011928 ECSP12011928A (es) 2009-10-27 2012-05-28 Vacuna de adn contra el virus de la fiebre amarilla
US15/204,077 US10124052B2 (en) 2009-10-27 2016-07-07 DNA vaccine against virus of Yellow Fever
US16/146,369 US10888612B2 (en) 2009-10-27 2018-09-28 DNA vaccine against virus of Yellow Fever

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
BRPI0905645A BRPI0905645B8 (pt) 2009-10-27 2009-10-27 vacina de dna contra o vírus da febre amarela

Publications (3)

Publication Number Publication Date
BRPI0905645A2 BRPI0905645A2 (pt) 2011-06-21
BRPI0905645B1 BRPI0905645B1 (pt) 2020-04-28
BRPI0905645B8 true BRPI0905645B8 (pt) 2021-05-25

Family

ID=43922652

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0905645A BRPI0905645B8 (pt) 2009-10-27 2009-10-27 vacina de dna contra o vírus da febre amarela

Country Status (11)

Country Link
US (3) US9393296B2 (pt)
EP (1) EP2495325B1 (pt)
AU (1) AU2010312258B2 (pt)
BR (1) BRPI0905645B8 (pt)
CA (1) CA2778893C (pt)
CL (1) CL2012001093A1 (pt)
EC (1) ECSP12011928A (pt)
ES (1) ES2605654T3 (pt)
PE (1) PE20130341A1 (pt)
WO (1) WO2011050431A2 (pt)
ZA (1) ZA201203862B (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2022208435A1 (en) 2021-01-18 2023-08-10 Conserv Bioscience Limited Coronavirus immunogenic compositions, methods and uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI9701774B8 (pt) * 1997-04-11 2015-09-29 Fundação Oswaldo Cruz Fiocruz cdna mutante e infeccioso do vírus da febre amarela, constructo de dna, vírus recombinante de febre amarela e vacina para humanos contra infecções de febre amarela.
US7064842B1 (en) * 1999-01-13 2006-06-20 Olympus Optical Co., Ltd. Optical displacement sensor and optical encoder
US6432411B1 (en) * 1999-07-13 2002-08-13 Hawaii Biotechnology Group Recombinant envelope vaccine against flavivirus infection
US6357374B1 (en) * 2000-07-21 2002-03-19 Cortana Corporation Method and apparatus for increasing the effectiveness and efficiency of multiple boundary layer control techniques
GB2372991B (en) 2001-03-09 2004-11-17 Fiocruz Fundacao Oswaldo Cruz Flavivirus expression vector
DK1385538T3 (da) * 2001-04-05 2013-04-29 Univ Johns Hopkins Kimære vacciner omfattende det lumenale domæne fra LAMP-1 eller LAMP-2
EP1454988A1 (en) * 2003-03-03 2004-09-08 Institut National De La Sante Et De La Recherche Medicale (Inserm) Infectious flavivirus pseudo-particles containing functional prM-E envelope proteins
WO2008089144A2 (en) * 2007-01-12 2008-07-24 The Government Of The United States, As Represented By The Secretary Of Health And Human Services Improved dna vaccination protocols

Also Published As

Publication number Publication date
PE20130341A1 (es) 2013-04-24
US20200188503A9 (en) 2020-06-18
WO2011050431A2 (pt) 2011-05-05
US20190015499A1 (en) 2019-01-17
US9393296B2 (en) 2016-07-19
US10888612B2 (en) 2021-01-12
AU2010312258B2 (en) 2017-06-08
WO2011050431A3 (pt) 2011-09-15
US10124052B2 (en) 2018-11-13
EP2495325A4 (en) 2013-06-05
US20120308603A1 (en) 2012-12-06
BRPI0905645A2 (pt) 2011-06-21
AU2010312258A1 (en) 2012-06-21
CA2778893A1 (en) 2011-05-05
BRPI0905645B1 (pt) 2020-04-28
EP2495325B1 (en) 2016-08-31
CA2778893C (en) 2019-11-26
CL2012001093A1 (es) 2012-10-19
EP2495325A2 (en) 2012-09-05
ES2605654T3 (es) 2017-03-15
ZA201203862B (en) 2013-01-30
US20160324953A1 (en) 2016-11-10
ECSP12011928A (es) 2013-01-31
EP2495325A9 (en) 2013-03-20

Similar Documents

Publication Publication Date Title
Burmakina et al. African swine fever virus serotype-specific proteins are significant protective antigens for African swine fever
Bodewes et al. Animal models for the preclinical evaluation of candidate influenza vaccines
BR112018017307A2 (pt) molécula de ácido nucleico isolada, composição, e, métodos para indução de uma resposta imune contra um zika vírus, para tratamento de um indivíduo e para prevenção de uma infecção por zika vírus
BR112013032723A2 (pt) antígenos amplamente reativos computacionalmente otimizados para influenza h1n1
MX346245B (es) Proteina de fusion que comprende el mutante crm197 no toxico de toxina de difteria.
BRPI1008692B8 (pt) anticorpo antagonista tendo especificidade para ox40 humano, sequência de dna isolado, vetor de clonagem ou de expressão, célula hospedeira, processo para a produção do referido anticorpo, composição farmacêutica, uso do 5 referido anticorpo e proteína de fusão
MY173004A (en) Mycobacterial antigen vaccine
MX2013010620A (es) Adenovirus de aves del serotipo 4 (fadv-4) no patogénico y vector viral del mismo.
BR112012008946A2 (pt) sequência polinucletídica isolada , molécula pollinucleotídica de rna, vetor ou plasmídeo , célula hospedeira , vírus a ser expresso , vacina , polipetídeo e composição de vacina
BR112015002131A8 (pt) Vírus vaccinia ankara modificado (mva) recombinante, composição farmacêutica e uso do referido mva recombinante
Kim et al. Influenza M2 virus-like particles confer a broader range of cross protection to the strain-specific pre-existing immunity
Rohde et al. New Orf virus (Parapoxvirus) recombinant expressing H5 hemagglutinin protects mice against H5N1 and H1N1 influenza A virus
BR112015000585A8 (pt) método para preparar uma cepa mutante de mycoplasma hyopneumoniae, vetores, cepa mutante, vacina, kit de vacinação e usos do vetor e da cepa mutante
BR112015022582A2 (pt) molécula de ácido nucleico, plasmídeo, vacina, e, uso de um plasmídeo
BR112012021650A2 (pt) "parvovírus recombinante atenuado, vacina para a proteção de animais contra infecção com parvovírus, método para a obtenção de um parvovírus recombinante, e, uso de uma vacina."
BRPI0813313A8 (pt) Vetor poxvírus de racum recombinante, vacina da raiva recombinante, métodos para induzir uma resposta imunoprotetora para a raiva em um mamífero, e para produzir um vetor poxvírus de racum recombinante, e, plasmídeo pfd2003-gpv-pv.
Gillam et al. Epitope selection and their placement for increased virus neutralization in a novel vaccination strategy for porcine epidemic diarrhea virus utilizing the Hepatitis B virus core antigen
EA201690115A1 (ru) Комбинированные иммуногенные композиции
BR112016007390A2 (pt) vacina de haemophilus parasuis sorotipo tipo quatro
Yang et al. Protection against influenza H7N9 virus challenge with a recombinant NP–M1–HSP60 protein vaccine construct in BALB/c mice
CO6541529A2 (es) Método, plasmideo y composición para inducir una respuesta inmune contra virus de la dengue basado en vacunas de adn y virus quimericos
BR112013013016A2 (pt) modulação de imunogenicidade de antígeno pela eliminação de epítopos reconhecidos pelas células nkt14
BR112018015912A2 (pt) vírus da vacina da síndrome respiratória e reprodutiva porcina
WO2018102774A8 (en) Pneumococcal vaccine combining selected alpha helical domains and proline rich domains of pneumococcal surface protein a
BRPI0905645B8 (pt) vacina de dna contra o vírus da febre amarela

Legal Events

Date Code Title Description
B03A Publication of a patent application or of a certificate of addition of invention [chapter 3.1 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 28/04/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 27/10/2009 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B15V Prolongation of time limit allowed
B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 12A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2641 DE 17-08-2021 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.